Profound Medical Corp. (PROF)
| Previous Close | 7.45 |
| Open | 7.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 7.37 - 7.50 |
| 52 Week Range | 7.11 - 15.49 |
| Volume | |
| Avg. Volume | 29,784 |
| Market Cap | 183.217M |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.29 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.61 |
GlobeNewswireProfound Medical Annual General Meeting of Shareholders Voting Results
TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the “Meeting”). A total of 15,336,388 common shares, representing 62.78% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company’s management information
- GlobeNewswire
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training images – – Validated in standalone and multi-reader, multi-case clinical studies conducted by world-renowned experts – – Urologists testing this TULSA-AI module improved their segmentation accuracy and were 32% faster in their contours – TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a
Simply Wall St.Profound Medical First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Profound Medical ( TSE:PRN ) First Quarter 2024 Results Key Financial Results Net loss: US$6.20m (loss narrowed by 8.0...
